Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials
Patient priorities in COPD exacerbation trial outcomes
Introduction: Importance of patient perspectives
Introduction: Patient perspectives are essential to establish relevant outcomes in trials assessing COPD treatments.
Aim: Outcomes prioritised by patients with COPD
Aim: To assess which trial outcomes for exacerbation treatments are most important for patients with COPD.
Methods: Semi-structured interviews in COPD patients
Methods: Patients with COPD underwent semi-structured interviews where they stated what outcomes should be prioritised in clinical trials.
Comparisons were made between patients with at least one COPD hospitalisation and patients with no hospitalisations in the preceding year.
Results: Chronic symptoms and functional impact
Results: Semi-structured interviews were conducted for 70 patients in 11 countries across 4 continents (average age 66.7 years, 79.2% male).
45 patients had at least 1 admission in the previous year. 8 out of the 10 most frequently chosen outcomes focussed on chronic symptoms, such as dyspnoea (90.0%), and specific aspects affecting quality of life and function, such as reduced walking distance (70.0%) and impact on social life (57.1%).
Patients with recent hospitalisations more frequently prioritised specific components of quality of life and function. Dyspnoea was most prioritised in both groups.
Conclusions: Quality of life and function as trial outcomes
Conclusions: COPD exacerbations trials should more consistently assess the individual outcomes which contribute to overall quality of life and function, including dyspnoea.
The outcomes highlighted align with the ERS statement on a core outcome set for trials on COPD exacerbation treatments.
Authors
Sachin Ananth, Fekri Abroug, Alvar Agusti, Per Bakke, Konstantinos Bartziokas, Bianca Beghe, Andras Bikov, Thomas Bradbury, Guy Brusselle, Cordula Cadus, Courtney Coleman, Marco Contoli, Alexandru Corlateanu, Olga Corlateanu, Gerard J. Criner, Balazs Csoma, Alexander Emelyanov, Rosa Faner, Gustavo Fernandez Romero, Zeineb Hammouda, Peter Horváth, Arturo Huerta Garcia, Michael Jacobs, Christine Jenkins, Guy Joos, Olga Kharevich, Konstantinos Kostikas, Elena Lapteva, Zsofia Lazar, Joerg D. Leuppi, Carol Liddle, John Linnell, Alejandra López-Giraldo, Vanessa M. Mcdonald, Rune Nielsen, Alberto Papi, Isabel Saraiva, Galina Sergeeva, Agni Sioutkou, Pradeesh Sivapalan, Elizabeth Stovold, Hao Wang, Fuqiang Wen, Janelle Yorke, Paula R. Williamson, Jørgen Vestbo, Jens-Ulrik Jensen, Alexander G. Mathioudakis
Read more details at
Fecha de publicación
Published online 18 November 2025
Categorías asociadas al artículo
Noticias relacionadas
Vídeo de la Presentación de las Novedades GOLD 2026
Video de la presentación «Novedades GOLD 2026», en el que se trataron, entre otros aspectos: cambios en diagnóstico de la EPOC, tratamiento, comparativa con GESEPOC, etc.
Treatable Traits. Why, What, How?
Discover how the Treatable Traits approach transforms the management of asthma, bronchiectasis, and COPD through personalized precision medicine strategies.
Diagnostic Metabolomic Profiling of COPD as Potential Biomarkers in Older and Younger Patients
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
COPD multimorbidity management: A person-centred clinical approach to the multimorbid patient with COPD
Expert consensus on patient-centred strategies to manage multimorbidity in COPD, aiming to improve outcomes and reduce disease burden.
Chronic Airways Assessment Test (CAAT)
The CAAT is a standardized 8-item questionnaire to assess health status in people with asthma, COPD, and other airway diseases. Now validated beyond COPD.
Imagen desarrollada ChatGPT